Breadcrumbs

Sarcoma - oncology

Soft Tissue Sarcoma

Protocol Administration at chemotherapy unit level Review date
Angiosarcoma locally advanced or metastatic PACLItaxel Medium March 2021
Liposarcoma advanced or metastatic eribulin Medium September 2021
Soft tissue sarcoma advanced pazopanib Low September 2022
Soft tissue sarcoma locally advanced or metastatic DOXOrubicin Medium March 2020
Soft tissue sarcoma locally advanced or metastatic DOXOrubicin and IFOSFamide Medium June 2022

Bone Sarcoma

Protocol Administration at chemotherapy unit level Review date
Ewing sarcoma recurrent or metastatic irinotecan and temozolomide
Medium September 2022
Ewing sarcoma IE (iFOSFamide and etoposide) (part 2 of VDC/IE)
High June 2022
Ewing sarcoma VAC (vinCRISTine daCTINomycin CYCLOPHOSPHamide) (part 2a of VIDE followed by VAC or VAI)
High
June 2022
Ewing sarcoma VAI (vinCRISTine daCTINomycin iFOSFamide) (part 2b of VIDE followed by VAC or VAI)
High
June 2022
Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE)
High
June 2022
Ewing sarcoma VIDE (vinCRISTine iFOSFamide DOXOrubicin etoposide) (part 1 of VIDE followed by VAC or VAI)
High
June 2022
Giant cell tumour of bone denosumab Low September 2021
Osteosarcoma MAP (methotrexate, DOXOrubicin, cISplatin)
Medium December 2021

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Local radiotherapy services required
  4. Non-formulary drug included in the protocol
  5. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.

^ Back to top